Title |
Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression
|
---|---|
Published in |
BMC Cancer, July 2006
|
DOI | 10.1186/1471-2407-6-181 |
Pubmed ID | |
Authors |
Teri L Larkins, Marchele Nowell, Shailesh Singh, Gary L Sanford |
Abstract |
Cyclooxygenase (COX) is the rate-limiting enzyme that catalyzes the formation of prostaglandins. The inducible isoform of COX (COX-2) is highly expressed in aggressive metastatic breast cancers and may play a critical role in cancer progression (i.e. growth and metastasis). However, the exact mechanism(s) for COX-2-enhanced metastasis has yet to be clearly defined. It is well established that one of the direct results of COX-2 action is increased prostaglandin production, especially prostaglandin E2 (PGE2). Here, we correlate the inhibition of COX-2 activity with decreased breast cancer cell proliferation, migration, invasion and matrix metalloproteinase (MMP) expression. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 1% |
Lebanon | 1 | 1% |
United States | 1 | 1% |
Italy | 1 | 1% |
Unknown | 65 | 94% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 23 | 33% |
Student > Master | 11 | 16% |
Student > Bachelor | 7 | 10% |
Researcher | 6 | 9% |
Student > Doctoral Student | 4 | 6% |
Other | 9 | 13% |
Unknown | 9 | 13% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 24 | 35% |
Biochemistry, Genetics and Molecular Biology | 15 | 22% |
Medicine and Dentistry | 10 | 14% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
Chemistry | 2 | 3% |
Other | 3 | 4% |
Unknown | 12 | 17% |